Last Updated: November 16, 2026

Investigational Drug Information for Pridopidine

« Back to Dashboard


What is the drug development status for Pridopidine?

Pridopidine is an investigational drug.

There have been 11 clinical trials for Pridopidine. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2026.

The most common disease conditions in clinical trials are Huntington Disease, Amyotrophic Lateral Sclerosis, and Motor Neuron Disease. The leading clinical trial sponsors are Prilenia, Teva Branded Pharmaceutical Products, R&D Inc., and Merit E. Cudkowicz, MD.

There are one hundred and eight US patents protecting this investigational drug and four hundred and sixty-five international patents.

Recent Clinical Trials for Pridopidine
TitleSponsorPhase
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALSFerrer Internacional S.A.PHASE3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALSPrileniaPHASE3
HEALEY ALS Platform Trial - Regimen D PridopidinePrilenia TherapeuticsPhase 2/Phase 3

See all Pridopidine clinical trials

Clinical Trial Summary for Pridopidine

Top disease conditions for Pridopidine
Top clinical trial sponsors for Pridopidine

See all Pridopidine clinical trials

US Patents for Pridopidine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pridopidine ⤷  Start Trial Schizophrenia-associated genetic loci identified in genome wide association studies and methods of use thereof Childrens Hospital of Philadelphia CHOP ⤷  Start Trial
Pridopidine ⤷  Start Trial Analogs of pridopidine, their preparation and use Prilenia Neurotherapeutics Ltd , Nobel Chemicals AB ⤷  Start Trial
Pridopidine ⤷  Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.